| RVPH - Reviva Pharmaceuticals Holdings Inc Ordinary Shares (Healthcare: Biotechnology) | Projected Earnings Date: 2024-08-16 (Delayed quote data 2025-06-27) |
|
|
|||||||||||||||||
|
|
|
| Company Profile | |
| Reviva Pharmaceuticals Holdings Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of internally discovered therapies that address unmet medical needs in the areas of central nervous system, respiratory, and metabolic diseases. The company is currently focused on the development of its lead product candidate, RP5063, which targets schizophrenia, bipolar disorder, major depressive disorder, behavioral & psychotic symptoms, dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, and also respiratory indications such as pulmonary arterial hypertension & idiopathic pulmonary fibrosis. | |
| Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. |